Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Breast Neoplasms 1230Neoplasms 1040Carcinoma, Non-Small-Cell Lung 757Prostatic Neoplasms 697Colorectal Neoplasms 598Lung Neoplasms 578Pancreatic Neoplasms 403Leukemia, Myeloid, Acute 399Neoplasm Metastasis 391Ovarian Neoplasms 373Multiple Myeloma 373Stomach Neoplasms 319Carcinoma, Hepatocellular 304Melanoma 284Brain Neoplasms 281Recurrence 280Squamous Cell Carcinoma of Head and Neck 269Head and Neck Neoplasms 240Endometrial Neoplasms 236Glioblastoma 235Triple Negative Breast Neoplasms 230Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Lymphoma 226Uterine Cervical Neoplasms 225Sarcoma 202Hematologic Neoplasms 201Urinary Bladder Neoplasms 197Esophageal Neoplasms 192Carcinoma, Renal Cell 191Lymphoma, Non-Hodgkin 177

Interventions

pembrolizumab 1osimertinib 1cemiplimab 1Vascular Endothelial Growth Factor A 1Paroxetine 1Paclitaxel 1Itraconazole 1Docetaxel 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Lethal Congenital Contracture Syndrome 2 × 1 year × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

NCT07111520 2026-05-05

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

BioNTech SE

Phase 1/2 Recruiting
420 enrolled
Thoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡